BioAge Labs Stock
BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist that promoted muscle metabolism and prevented muscle atrophy on bed rest in a Phase 1b trial.
Management Team
| Kristen Fortney Co-Founder, CEO |
| Eric Morgan Co-Founder, COO |
| Paul Rubin CMO, EVP of Research |
| Peng Leong CBO |
| Ann Neale CDO |
| Dav Goldstein CFO |
| BJ Sullivan Chief Strategy Officer |
